Occam Places Adrian Schreyer as CTO of Anagenex
In March of 2024, Occam placed Adrian Schreyer as CTO at Anagenex, a pioneering drug discovery company pairing large-scale data generation with proprietary artificial intelligence (AI) to discover the next generation of small molecule medicines.
Prior to joining Anagenex, he spent over a decade at Exscientia where he was a founding member of the team and went on to support the company through a successful IPO while building its AI team from scratch and eventually serving as the company’s Chief Technology Officer. The AI-enabled drug discovery engine he designed at Exscientia is one of the only AI platforms to drive compounds from discovery into the clinic. Adrian holds a B.Sc. in Applied Biology from the Bonn-Rhein-Sieg University of Applied Sciences and a Ph.D. in Structural Bioinformatics and Drug Discovery from the University of Cambridge.
Schreyer is the latest in a series of Occam placements at Anagenex including Ryan Kruger, CSO, Joe Franklin,SVP Early Discovery and Tito Serafini, Board Member.
Occam Global is an executive recruiting and leadership advisory firm with specialties across technological fields including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.